1,2-Bis[1-(3-methyl­sulfanyl-1,2,4-triazin-5-yl)ethyl­idene]diazane

The mol­ecule of the title compound, C12H14N8S2, has an N—N gauche conformation. The triazine rings are nearly coplanar with respect to the imide bonds [C—C—C—N torsion angles = −15.3 (3) and −15.8 (3)°] and they are twisted by 77.88 (7)°. The overall conformation of the mol­ecule is stabilized by intra­molecular C—H⋯N hydrogen bonding. The mol­ecular packing is influenced by π–π inter­actions of the triazine systems with a shortest centroid–centroid separation of 3.5242 (12) Å

Skuteczność ruksolitynibu w leczeniu chorych na mielofibrozę z chorobami współistniejącymi

Myelofibrosis (MF) is a heterogenous Philadelphia-myeloproliferative neoplasm that is characterized by bone marrow fibrosis and impaired hematopoiesis. Clinical hallmarks of MF are increased splenomegaly, cytopenias and general symptoms. Deregulation of JAK–STAT signaling pathway plays a key role in the pathogenesis of MF. Ruxolitinib is a selective and oral JAK1/JAK2 inhibitor that in clinical trials demonstrated significant efficacy in the reduction of clinical symptoms, improved the quality of life and increased overall survival of patients with MF.Mielofibroza (MF) jest heterogennym nowotworem układu krwiotwórczego, cechującym się brakiem chromosomu Filadelfia i włóknieniem szpiku oraz wynikającym z tego upośledzeniem hematopoezy. Objawami klinicznymi MF są powiększenie śledziony, cytopenie oraz objawy ogólne. W patogenezie MF szczególną rolę odgrywają zaburzenia szlaku JAK–STAT. Ruksolitynib jest selektywnym, doustnym inhibitorem JAK1/JAK2, który w badaniach klinicznych wykazał istotną skuteczność w zmniejszeniu objawów klinicznych, poprawie jakości życia oraz wydłużeniu całkowitego przeżycia chorych na MF

1,3-Dimethyl-5-methyl­sulfonyl-1H-pyrazolo­[4,3-e][1,2,4]triazine

In the title compound, C7H9N5O2S, the pyrazolo­[4,3-e][1,2,4]triazine fused-ring system is essentially planar [maximum deviation = 0.0420 (3) Å]. In the crystal, mol­ecules related by twofold axes are linked into a mol­ecular net via inter­molecular C—H⋯O and C—H⋯N hydrogen bonds. π–π inter­actions are observed between the triazine and pyrazole rings of mol­ecules related by the the twofold axis and inversion symmetry with centroid–centroid distances of 3.778 (3) and 3.416 (3) Å, respectively

CD200:CD200R Interactions and Their Importance in Immunoregulation

The molecule CD200, described many years ago as a naturally occurring immunomodulatory agent, capable of regulating inflammation and transplant rejection, has attracted additional interest over the past years with the realization that it may also serve as an important marker for progressive malignancy. A large body of evidence also supports the hypothesis that this molecule can contribute to immunoregulation of, among other diseases, infection, autoimmune disease and allergy. New data have also come to light to characterize the receptors for CD200 (CD200R) and their potential mechanism(s) of action at the biochemical level, as well as the description of a novel natural antagonist of CD200, lacking the NH2-terminal region of the full-length molecule. Significant controversies exist concerning the relative importance of CD200 as a ligand for all reported CD200Rs. Nevertheless, some progress has been made in the identification of the structural constraints determining the interaction between CD200 and CD200R, and this information has in turn proved of use in developing novel small molecule agonists/antagonists of the interaction. The review below highlights many of these newer findings, and attempts to place them in the broad context of our understanding of the role of CD200-CD200R interactions in a variety of human diseases